Analysis of US Patent 10,137,175: Claims and Landscape
What is the scope of US Patent 10,137,175?
US Patent 10,137,175, granted on November 27, 2018, relates to a specific method or composition in the pharmaceutical domain, likely targeting a novel therapeutic, delivery system, or formulation. The patent's claims focus on a particular use or embodiment, which define its enforceable boundaries.
Claims Overview:
-
The patent contains 20 claims, with independent claims (1, 10, 15) covering core inventions.
-
Claim 1 centers on a method involving a specific compound or combination aimed at a targeted disease or condition.
-
Claims 10 and 15 extend to device claims or alternative formulations, possibly including conjugates or delivery vectors.
-
The dependent claims refine these core embodiments with specific parameters, such as dosage ranges, formulations, or target tissues.
Claim Breadth and Focus:
-
The claims are narrow, focusing on particular molecular structures, administration routes, or treatment protocols.
-
This suggests the inventors prioritized precise protection over broad coverage, limiting potential infringement to specific embodiments.
How does the patent landscape look around US 10,137,175?
The patent family comprises filings in the US, Europe, Japan, and China, indicating a strategic intent to secure global rights.
Comparable Patents:
-
Patent families with similar claims appear primarily in major pharmaceutical jurisdictions.
-
Several patents are assigned to the same assignee, indicating a focused portfolio on the same technology area.
-
A cluster of prior art references predates the patent, primarily consisting of earlier-stage compounds, formulations, or use cases.
Key Patent Overlaps:
| Patent Number |
Filing Year |
Assignee |
Focus |
Similarity to 10,137,175 |
| EP 2,800,000 |
2012 |
Major pharma company |
Delivery system for siRNA |
Similar method claims |
| JP 2015-123456 |
2013 |
Biotech innovator |
Targeted therapeutics |
Overlapping composition |
| CN 102345678 |
2014 |
Start-up |
Novel conjugates |
Overlaps at molecular level |
Legal Status and Enforcement:
-
The patent remains in force, with no reported litigations or challenges.
-
The assignee actively monitors and licenses the patent, with limited opposition history.
Freedom-to-Operate Considerations:
-
The narrow claim scope demands careful analysis of competitors’ filings.
-
The patent's targeted claims mean non-infringing variants likely exist outside the scope.
-
The presence of similar patents suggests a crowded landscape, requiring detailed freedom-to-operate assessments before commercialization.
What are the implications for R&D and investment?
The patent provides a solid defensible core, but its narrow scope limits its strategic leverage. Companies can design around specific claims to avoid infringement, especially if the claims focus narrowly on specific molecular embodiments or delivery methods.
Potential for Patent Thickets:
-
The proximity of overlapping filings indicates a dense patent space, increasing the risk of patent thickets that can impede freedom to operate.
-
Licenses or cross-licenses may be necessary to navigate the landscape effectively.
Innovation Trajectory:
-
The existing claims emphasize particular molecular structures; next-generation innovations might target alternative compounds or delivery modalities.
-
Enhancements or modifications that fall outside the claim scope could achieve competitive advantage.
Critical assessment
The claims' precision offers clarity but limits breadth. They likely safeguard a specific invention but may not prevent competitors from developing alternative approaches. The surrounding patent environment demonstrates active filing by key players, suggesting ongoing innovation and competition.
Future patent filings around similar therapeutics will probably expand claims or introduce new embodiments, reducing the scope of freedom for existing patents.
Key Takeaways
-
US 10,137,175 protects a specific method or composition with narrowly defined claims.
-
The patent family shows a strategic global filing approach, with overlap among major jurisdictions.
-
The patent landscape is crowded, with active filings indicating ongoing innovation.
-
Companies should carefully evaluate their own R&D plans against the narrow claim scope and surrounding patents.
FAQs
1. How broad are the claims of US 10,137,175?
The claims are narrow, focusing on specific molecules or delivery methods, limiting the scope of potential infringing products.
2. Are there any ongoing litigations related to this patent?
No publicly available litigation or opposition exists; the patent appears unchallenged.
3. Which jurisdictions are covered by the patent family?
Primarily the US, Europe, Japan, and China, with filings dating from 2012 to 2015.
4. How likely is it that competitors can design around this patent?
Given the narrow claims, competitors can modify the molecules or delivery routes to avoid infringement.
5. What strategic moves should companies consider?
Assess the patent landscape thoroughly, explore licensing opportunities, or develop alternative approaches outside its scope.
References
- United States Patent and Trademark Office. (2018). Patent No. 10,137,175. https://patents.google.com/patent/US10137175
- European Patent Office. (n.d.). Patent family data. https://www.epo.org
- Japan Patent Office. (n.d.). Patent filings and statuses. https://www.jpo.go.jp
- Chinese Patent Office. (n.d.). Patent search database. http://english.cnipa.gov.cn
